A comparison of subcutaneous versus intramuscular DMPA as a choice of contraceptive method to see the difference in efficacy of dmpa in both modes of injections among reproductive women

A comparison of subcutaneous versus intramuscular depot medroxyprogesterone acetate as a choice of contraceptive method - NIL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070627

Enrollment

100

Registered

2024-07-15

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: women receiving subcutaneous DMPA 104 mg in 0.65 ml every 3 monthly: follow up for 12 months Control Intervention1: women receiving intramuscular DMPA 150 mg in 1 ml every 3 monthly: fo

Eligibility

Inclusion criteria

Inclusion criteria: Women giving informed consent for receiving DMPA and ready to follow up visits every 3 months and are falling in category 1 or 2 of WHO Medical Eligibility Criteria for injection DMPA in following phases; a. Post menstrual b. Post abortal c. 6 weeks post delivery.

Exclusion criteria

Exclusion criteria: Women with prior history of menstrual irregularities.

Design outcomes

Primary

Measure	Time frame
(1) Percentage of women willing to continue subcutaneous Depot medroxyprogesterone acetate (DMPA) as contraceptive method. (2) Percentage of women willing to continue intramuscular DMPA as contraceptive method Timepoint: 12 months	—

Secondary

Measure	Time frame
(1) Percentage of women having side effects with subcutaneous DMPA. (2) Percentage of women having side effects with intramuscular DMPA. Timepoint: 12 months	—

Countries

India

Contacts

Public ContactDr Y M MALA

maulana azad medical college

ym_mala@yahoo.com9968604347

Outcome results